Use of NK-1 receptor antagonist serlopitant in pruritus
View Patent ↗The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
1. A pharmaceutical composition in the form of a tablet, comprising serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof, microcrystalline cellulose, mannitol, croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate.
2. The pharmaceutical composition of claim 1 , wherein the tablet comprises from about 1 mg to about 7.5 mg of serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof.
3. The pharmaceutical composition of claim 2 , wherein the tablet comprises about 1 mg or about 5 mg of serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof.
4. The pharmaceutical composition of claim 3 , wherein the tablet is coated.
5. A transdermal pharmaceutical composition comprising serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof, and a pharmaceutically acceptable carrier or excipient.
6. The transdermal pharmaceutical composition of claim 5 , which comprises a permeation enhancer.
7. The transdermal pharmaceutical composition of claim 5 , which is in the form of a spray, a gel, a jelly, a liniment, a lotion, a cream, a foam, an ointment or a paste.
8. The transdermal pharmaceutical composition of claim 5 , which is in the form of a transdermal patch.
9. The transdermal pharmaceutical composition of claim 6 , which is in the form of a spray, a gel, a jelly, a liniment, a lotion, a cream, a foam, an ointment or a paste.
10. The transdermal pharmaceutical composition of claim 6 , which is in the form of a transdermal patch.